APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for PrEP

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for PrEP Industry Growth and Trends Forecast to 2032

28 December 2025109 pages

Choose your research edition.

Industry ResearchDrugs for PrEP Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for PrEP Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Drugs for PrEP Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for PrEP Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for PrEP Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Drugs for PrEP market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for PrEP is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for PrEP include Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, North China Pharmaceutical, Chengdu Brilliant Pharmaceutical, Anhui Baker Biopharmaceutical, Zydus, ViiV Healthcare, Teva and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for PrEP market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for PrEP market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for PrEP market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for PrEP.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Drugs for PrEP market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for PrEP Market by Company

Chia Tai Tianqing Pharmaceutical

Qilu Pharmaceutical

North China Pharmaceutical

Chengdu Brilliant Pharmaceutical

Anhui Baker Biopharmaceutical

Zydus

ViiV Healthcare

Teva

Mylan

Gilead Sciences

Aurobindo Pharma

Amneal Pharmaceuticals

Drugs for PrEP Segment by Type

Oral Drugs

Injections

Drugs for PrEP Segment by Application

Hospital and Clinic

Pharmacy

Other

Drugs for PrEP Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for PrEP market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for PrEP and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for PrEP.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for PrEP manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Drugs for PrEP in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Drugs Table 2. Major Company of Injections Table 3. Global Drugs for PrEP Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 5. Global Drugs for PrEP Sales Market Share in Volume by Type (2021-2026) Table 6. Global Drugs for PrEP Sales by Type (2021-2026) & (US$ Million) Table 7. Global Drugs for PrEP Sales Market Share in Value by Type (2021-2026) Table 8. Global Drugs for PrEP Price by Type (2021-2026) & (US$/Unit) Table 9. Global Drugs for PrEP Sales by Type (2027-2032) & (K Units) Table 10. Global Drugs for PrEP Sales Market Share in Volume by Type (2027-2032) Table 11. Global Drugs for PrEP Sales by Type (2027-2032) & (US$ Million) Table 12. Global Drugs for PrEP Sales Market Share in Value by Type (2027-2032) Table 13. Global Drugs for PrEP Price by Type (2027-2032) & (US$/Unit) Table 14. North America Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 15. North America Drugs for PrEP Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 17. Europe Drugs for PrEP Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Drugs for PrEP Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 21. Latin America Drugs for PrEP Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Drugs for PrEP Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Drugs for PrEP Sales by Type (2021-2026) & (US$ Million) Table 24. Drugs for PrEP Industry Trends Table 25. Drugs for PrEP Industry Drivers Table 26. Drugs for PrEP Industry Opportunities and Challenges Table 27. Drugs for PrEP Industry Restraints Table 28. Global Drugs for PrEP Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Drugs for PrEP Revenue Market Share by Company (2021-2026) Table 30. Global Drugs for PrEP Sales by Company (2021-2026) & (K Units) Table 31. Global Drugs for PrEP Sales Share by Company (2021-2026) Table 32. Global Drugs for PrEP Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Drugs for PrEP Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Drugs for PrEP Major Company Production Sites and Headquarters Table 35. Global Drugs for PrEP Company, Product Type & Application Table 36. Global Drugs for PrEP Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Drugs for PrEP by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Drugs for PrEP Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Drugs for PrEP Sales by Region (2021-2026) & (K Units) Table 41. Global Drugs for PrEP Sales Market Share in Volume by Region (2021-2026) Table 42. Global Drugs for PrEP Sales by Region (2021-2026) & (US$ Million) Table 43. Global Drugs for PrEP Sales Market Share in Value by Region (2021-2026) Table 44. Global Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Drugs for PrEP Sales by Region (2027-2032) & (K Units) Table 46. Global Drugs for PrEP Sales Market Share in Volume by Region (2027-2032) Table 47. Global Drugs for PrEP Sales by Region (2027-2032) & (US$ Million) Table 48. Global Drugs for PrEP Sales Market Share in Value by Region (2027-2032) Table 49. Global Drugs for PrEP Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Drugs for PrEP Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 52. Global Drugs for PrEP Sales Market Share in Volume by Application (2021-2026) Table 53. Global Drugs for PrEP Sales by Application (2021-2026) & (US$ Million) Table 54. Global Drugs for PrEP Sales Market Share in Value by Application (2021-2026) Table 55. Global Drugs for PrEP Price by Application (2021-2026) & (US$/Unit) Table 56. Global Drugs for PrEP Sales by Application (2027-2032) & (K Units) Table 57. Global Drugs for PrEP Sales Market Share in Volume by Application (2027-2032) Table 58. Global Drugs for PrEP Sales by Application (2027-2032) & (US$ Million) Table 59. Global Drugs for PrEP Sales Market Share in Value by Application (2027-2032) Table 60. Global Drugs for PrEP Price by Application (2027-2032) & (US$/Unit) Table 61. North America Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 62. North America Drugs for PrEP Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 64. Europe Drugs for PrEP Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Drugs for PrEP Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 68. Latin America Drugs for PrEP Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Drugs for PrEP Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Drugs for PrEP Sales by Application (2021-2026) & (US$ Million) Table 71. Chia Tai Tianqing Pharmaceutical Company Information Table 72. Chia Tai Tianqing Pharmaceutical Business Overview Table 73. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio Table 75. Chia Tai Tianqing Pharmaceutical Recent Development Table 76. Qilu Pharmaceutical Company Information Table 77. Qilu Pharmaceutical Business Overview Table 78. Qilu Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Qilu Pharmaceutical Drugs for PrEP Product Portfolio Table 80. Qilu Pharmaceutical Recent Development Table 81. North China Pharmaceutical Company Information Table 82. North China Pharmaceutical Business Overview Table 83. North China Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. North China Pharmaceutical Drugs for PrEP Product Portfolio Table 85. North China Pharmaceutical Recent Development Table 86. Chengdu Brilliant Pharmaceutical Company Information Table 87. Chengdu Brilliant Pharmaceutical Business Overview Table 88. Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio Table 90. Chengdu Brilliant Pharmaceutical Recent Development Table 91. Anhui Baker Biopharmaceutical Company Information Table 92. Anhui Baker Biopharmaceutical Business Overview Table 93. Anhui Baker Biopharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio Table 95. Anhui Baker Biopharmaceutical Recent Development Table 96. Zydus Company Information Table 97. Zydus Business Overview Table 98. Zydus Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Zydus Drugs for PrEP Product Portfolio Table 100. Zydus Recent Development Table 101. ViiV Healthcare Company Information Table 102. ViiV Healthcare Business Overview Table 103. ViiV Healthcare Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ViiV Healthcare Drugs for PrEP Product Portfolio Table 105. ViiV Healthcare Recent Development Table 106. Teva Company Information Table 107. Teva Business Overview Table 108. Teva Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Teva Drugs for PrEP Product Portfolio Table 110. Teva Recent Development Table 111. Mylan Company Information Table 112. Mylan Business Overview Table 113. Mylan Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Mylan Drugs for PrEP Product Portfolio Table 115. Mylan Recent Development Table 116. Gilead Sciences Company Information Table 117. Gilead Sciences Business Overview Table 118. Gilead Sciences Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Gilead Sciences Drugs for PrEP Product Portfolio Table 120. Gilead Sciences Recent Development Table 121. Aurobindo Pharma Company Information Table 122. Aurobindo Pharma Business Overview Table 123. Aurobindo Pharma Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Aurobindo Pharma Drugs for PrEP Product Portfolio Table 125. Aurobindo Pharma Recent Development Table 126. Amneal Pharmaceuticals Company Information Table 127. Amneal Pharmaceuticals Business Overview Table 128. Amneal Pharmaceuticals Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Amneal Pharmaceuticals Drugs for PrEP Product Portfolio Table 130. Amneal Pharmaceuticals Recent Development Table 131. North America Drugs for PrEP Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. North America Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 133. North America Drugs for PrEP Sales Market Share by Country (2021-2026) Table 134. North America Drugs for PrEP Sales Forecast by Country (2027-2032) & (K Units) Table 135. North America Drugs for PrEP Sales Market Share Forecast by Country (2027-2032) Table 136. North America Drugs for PrEP Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America Drugs for PrEP Market Size by Country (2021-2026) & (US$ Million) Table 138. North America Drugs for PrEP Market Share by Country (2021-2026) Table 139. North America Drugs for PrEP Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America Drugs for PrEP Market Share Forecast by Country (2027-2032) Table 141. Europe Drugs for PrEP Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Europe Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 143. Europe Drugs for PrEP Sales Market Share by Country (2021-2026) Table 144. Europe Drugs for PrEP Sales Forecast by Country (2027-2032) & (K Units) Table 145. Europe Drugs for PrEP Sales Market Share Forecast by Country (2027-2032) Table 146. Europe Drugs for PrEP Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe Drugs for PrEP Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe Drugs for PrEP Market Share by Country (2021-2026) Table 149. Europe Drugs for PrEP Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe Drugs for PrEP Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Drugs for PrEP Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 153. Asia-Pacific Drugs for PrEP Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific Drugs for PrEP Sales Forecast by Country (2027-2032) & (K Units) Table 155. Asia-Pacific Drugs for PrEP Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Drugs for PrEP Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Drugs for PrEP Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific Drugs for PrEP Market Share by Country (2021-2026) Table 159. Asia-Pacific Drugs for PrEP Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific Drugs for PrEP Market Share Forecast by Country (2027-2032) Table 161. Latin America Drugs for PrEP Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Latin America Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 163. Latin America Drugs for PrEP Sales Market Share by Country (2021-2026) Table 164. Latin America Drugs for PrEP Sales Forecast by Country (2027-2032) & (K Units) Table 165. Latin America Drugs for PrEP Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America Drugs for PrEP Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America Drugs for PrEP Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America Drugs for PrEP Market Share by Country (2021-2026) Table 169. Latin America Drugs for PrEP Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America Drugs for PrEP Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Drugs for PrEP Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Drugs for PrEP Sales by Country (2021-2026) & (K Units) Table 173. Middle East and Africa Drugs for PrEP Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa Drugs for PrEP Sales Forecast by Country (2027-2032) & (K Units) Table 175. Middle East and Africa Drugs for PrEP Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Drugs for PrEP Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Drugs for PrEP Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa Drugs for PrEP Market Share by Country (2021-2026) Table 179. Middle East and Africa Drugs for PrEP Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa Drugs for PrEP Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. Drugs for PrEP Distributors List Table 184. Drugs for PrEP Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Drugs for PrEP Image Figure 2. Global Drugs for PrEP Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for PrEP Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for PrEP Sales (2021-2032) & (K Units) Figure 5. Oral Drugs Image Figure 6. Global Oral Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Injections Image Figure 8. Global Injections Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Drugs for PrEP Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Drugs for PrEP Market Share by Type 2025 VS 2032 Figure 11. North America Drugs for PrEP Sales Market Share in Volume by Type in 2025 Figure 12. North America Drugs for PrEP Sales Market Share in Value by Type in 2025 Figure 13. Europe Drugs for PrEP Sales Market Share in Volume by Type in 2025 Figure 14. Europe Drugs for PrEP Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Drugs for PrEP Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Drugs for PrEP Sales Market Share in Value by Type in 2025 Figure 17. Latin America Drugs for PrEP Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Drugs for PrEP Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Drugs for PrEP Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Drugs for PrEP Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Drugs for PrEP Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 25. Pharmacy Image Figure 26. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Drugs for PrEP Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Drugs for PrEP Market Share by Application 2025 VS 2032 Figure 31. North America Drugs for PrEP Sales Market Share in Volume by Application in 2025 Figure 32. North America Drugs for PrEP Sales Market Share in Value by Application in 2025 Figure 33. Europe Drugs for PrEP Sales Market Share in Volume by Application in 2025 Figure 34. Europe Drugs for PrEP Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Drugs for PrEP Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Drugs for PrEP Sales Market Share in Value by Application in 2025 Figure 37. Latin America Drugs for PrEP Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Drugs for PrEP Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Drugs for PrEP Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Drugs for PrEP Sales Market Share in Value by Application in 2025 Figure 41. North America Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Drugs for PrEP Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Drugs for PrEP Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Drugs for PrEP Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Drugs for PrEP Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Drugs for PrEP Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Drugs for PrEP Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Drugs for PrEP Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Drugs for PrEP Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Drugs for PrEP Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Drugs for PrEP Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Drugs for PrEP Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Drugs for PrEP Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Drugs for PrEP Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Drugs for PrEP Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Drugs for PrEP Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Drugs for PrEP Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Drugs for PrEP Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Drugs for PrEP Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Qilu Pharmaceutical
  • North China Pharmaceutical
  • Chengdu Brilliant Pharmaceutical
  • Anhui Baker Biopharmaceutical
  • Zydus
  • ViiV Healthcare
  • Teva
  • Mylan
  • Gilead Sciences
  • Aurobindo Pharma
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for PrEP Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Drugs for PrEP Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Drugs for PrEP Market by Type
  6. 1.3.1 Oral Drugs
  7. 1.3.2 Injections
  8. 1.4 Global Drugs for PrEP Market Size by Type
  9. 1.4.1 Global Drugs for PrEP Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Drugs for PrEP Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Drugs for PrEP Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Drugs for PrEP Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Drugs for PrEP Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Drugs for PrEP Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Drugs for PrEP Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Drugs for PrEP Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Drugs for PrEP Industry Trends
  2. 2.2 Drugs for PrEP Industry Drivers
  3. 2.3 Drugs for PrEP Industry Opportunities and Challenges
  4. 2.4 Drugs for PrEP Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Drugs for PrEP Revenue (2021-2026)
  2. 3.2 Global Top Players by Drugs for PrEP Sales (2021-2026)
  3. 3.3 Global Top Players by Drugs for PrEP Price (2021-2026)
  4. 3.4 Global Drugs for PrEP Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for PrEP Major Company Production Sites & Headquarters
  6. 3.6 Global Drugs for PrEP Company, Product Type & Application
  7. 3.7 Global Drugs for PrEP Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for PrEP Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for PrEP Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for PrEP Tier 1, Tier 2, and Tier 3
4 Drugs for PrEP Regional Status and Outlook
  1. 4.1 Global Drugs for PrEP Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Drugs for PrEP Historic Market Size by Region
  3. 4.2.1 Global Drugs for PrEP Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Drugs for PrEP Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Drugs for PrEP Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Drugs for PrEP Forecasted Market Size by Region
  7. 4.3.1 Global Drugs for PrEP Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Drugs for PrEP Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Drugs for PrEP Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Drugs for PrEP by Application
  1. 5.1 Drugs for PrEP Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Drugs for PrEP Market Size by Application
  6. 5.2.1 Global Drugs for PrEP Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Drugs for PrEP Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Drugs for PrEP Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Drugs for PrEP Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Drugs for PrEP Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Drugs for PrEP Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Drugs for PrEP Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Drugs for PrEP Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chia Tai Tianqing Pharmaceutical
  2. 6.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 6.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 6.1.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio
  6. 6.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 6.2 Qilu Pharmaceutical
  8. 6.2.1 Qilu Pharmaceutical Company Information
  9. 6.2.2 Qilu Pharmaceutical Business Overview
  10. 6.2.3 Qilu Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Qilu Pharmaceutical Drugs for PrEP Product Portfolio
  12. 6.2.5 Qilu Pharmaceutical Recent Developments
  13. 6.3 North China Pharmaceutical
  14. 6.3.1 North China Pharmaceutical Company Information
  15. 6.3.2 North China Pharmaceutical Business Overview
  16. 6.3.3 North China Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 North China Pharmaceutical Drugs for PrEP Product Portfolio
  18. 6.3.5 North China Pharmaceutical Recent Developments
  19. 6.4 Chengdu Brilliant Pharmaceutical
  20. 6.4.1 Chengdu Brilliant Pharmaceutical Company Information
  21. 6.4.2 Chengdu Brilliant Pharmaceutical Business Overview
  22. 6.4.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio
  24. 6.4.5 Chengdu Brilliant Pharmaceutical Recent Developments
  25. 6.5 Anhui Baker Biopharmaceutical
  26. 6.5.1 Anhui Baker Biopharmaceutical Company Information
  27. 6.5.2 Anhui Baker Biopharmaceutical Business Overview
  28. 6.5.3 Anhui Baker Biopharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio
  30. 6.5.5 Anhui Baker Biopharmaceutical Recent Developments
  31. 6.6 Zydus
  32. 6.6.1 Zydus Company Information
  33. 6.6.2 Zydus Business Overview
  34. 6.6.3 Zydus Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Zydus Drugs for PrEP Product Portfolio
  36. 6.6.5 Zydus Recent Developments
  37. 6.7 ViiV Healthcare
  38. 6.7.1 ViiV Healthcare Company Information
  39. 6.7.2 ViiV Healthcare Business Overview
  40. 6.7.3 ViiV Healthcare Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 ViiV Healthcare Drugs for PrEP Product Portfolio
  42. 6.7.5 ViiV Healthcare Recent Developments
  43. 6.8 Teva
  44. 6.8.1 Teva Company Information
  45. 6.8.2 Teva Business Overview
  46. 6.8.3 Teva Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Teva Drugs for PrEP Product Portfolio
  48. 6.8.5 Teva Recent Developments
  49. 6.9 Mylan
  50. 6.9.1 Mylan Company Information
  51. 6.9.2 Mylan Business Overview
  52. 6.9.3 Mylan Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Mylan Drugs for PrEP Product Portfolio
  54. 6.9.5 Mylan Recent Developments
  55. 6.10 Gilead Sciences
  56. 6.10.1 Gilead Sciences Company Information
  57. 6.10.2 Gilead Sciences Business Overview
  58. 6.10.3 Gilead Sciences Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Gilead Sciences Drugs for PrEP Product Portfolio
  60. 6.10.5 Gilead Sciences Recent Developments
  61. 6.11 Aurobindo Pharma
  62. 6.11.1 Aurobindo Pharma Company Information
  63. 6.11.2 Aurobindo Pharma Business Overview
  64. 6.11.3 Aurobindo Pharma Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Aurobindo Pharma Drugs for PrEP Product Portfolio
  66. 6.11.5 Aurobindo Pharma Recent Developments
  67. 6.12 Amneal Pharmaceuticals
  68. 6.12.1 Amneal Pharmaceuticals Company Information
  69. 6.12.2 Amneal Pharmaceuticals Business Overview
  70. 6.12.3 Amneal Pharmaceuticals Drugs for PrEP Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Amneal Pharmaceuticals Drugs for PrEP Product Portfolio
  72. 6.12.5 Amneal Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Drugs for PrEP Sales by Country
  2. 7.1.1 North America Drugs for PrEP Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Drugs for PrEP Sales by Country (2021-2026)
  4. 7.1.3 North America Drugs for PrEP Sales Forecast by Country (2027-2032)
  5. 7.2 North America Drugs for PrEP Market Size by Country
  6. 7.2.1 North America Drugs for PrEP Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Drugs for PrEP Market Size by Country (2021-2026)
  8. 7.2.3 North America Drugs for PrEP Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Drugs for PrEP Sales by Country
  2. 8.1.1 Europe Drugs for PrEP Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Drugs for PrEP Sales by Country (2021-2026)
  4. 8.1.3 Europe Drugs for PrEP Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Drugs for PrEP Market Size by Country
  6. 8.2.1 Europe Drugs for PrEP Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Drugs for PrEP Market Size by Country (2021-2026)
  8. 8.2.3 Europe Drugs for PrEP Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Drugs for PrEP Sales by Country
  2. 9.1.1 Asia-Pacific Drugs for PrEP Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Drugs for PrEP Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Drugs for PrEP Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Drugs for PrEP Market Size by Country
  6. 9.2.1 Asia-Pacific Drugs for PrEP Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Drugs for PrEP Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Drugs for PrEP Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Drugs for PrEP Sales by Country
  2. 10.1.1 South America Drugs for PrEP Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Drugs for PrEP Sales by Country (2021-2026)
  4. 10.1.3 South America Drugs for PrEP Sales Forecast by Country (2027-2032)
  5. 10.2 South America Drugs for PrEP Market Size by Country
  6. 10.2.1 South America Drugs for PrEP Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Drugs for PrEP Market Size by Country (2021-2026)
  8. 10.2.3 South America Drugs for PrEP Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Drugs for PrEP Sales by Country
  2. 11.1.1 Middle East and Africa Drugs for PrEP Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Drugs for PrEP Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Drugs for PrEP Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Drugs for PrEP Market Size by Country
  6. 11.2.1 Middle East and Africa Drugs for PrEP Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Drugs for PrEP Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Drugs for PrEP Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Drugs for PrEP Value Chain Analysis
  2. 12.1.1 Drugs for PrEP Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Drugs for PrEP Production Mode & Process
  7. 12.2 Drugs for PrEP Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Drugs for PrEP Distributors
  10. 12.2.3 Drugs for PrEP Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst